Industry Intelligence
Daily intelligence on pharma market access — formulary decisions, reimbursement and payer policy, hospital pharmacy procurement, and the regulatory and pricing dynamics shaping patient access to medicines.
Despite price cuts and government programs, out-of-pocket GLP-1 costs remain prohibitive for most patients. New data reveals a fundamental affordability
Read More
January 2026 survey findings highlight systemic blind spot in pharmaceutical distribution. Only 20% of hospital pharmacies report full, real-time visibility
Read More
The FDA cleared tirzepatide (Mounjaro) to reduce cardiovascular death, heart attacks, and strokes in type 2 diabetes patients—marking a watershed
Read More
The FDA has approved Tauklarify, a new PET imaging tracer that detects tau tangles in patients being evaluated for Alzheimer’s
Read More
TrumpRx now lists 800+ drugs, but AMCP’s Adam Colborn says a discounted price means nothing if the local pharmacy won’t
Read More
FTC settlements with Express Scripts and CVS Caremark are forcing structural transparency into PBM operations — here’s what changes and
Read More
Employer contracts with the Big Three PBMs dropped nearly 10 points in a single year — and over half are
Read More
Three PBM-owned pharmacies control two-thirds of specialty drug dispensing revenue — here’s the full landscape access teams need to navigate.
Read More
Vizient and Premier alone represent over 60% of US hospital beds — here’s the full GPO landscape shaping formulary and
Read More
Three companies process 80% of all US prescription claims — here’s the full PBM and market access landscape hospital pharmacy
Read More